연구동향 분석

Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea

Hong Sun In Ryu Byung-Han Hong Kyung-Wook Bae In-Gyu Cho Oh-Hyun 2022년

논문상세정보
인용/피인용
' Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • COVID-19
  • Regdanvimab
  • monoclonal antibody
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
5,603 0

0.0%

' Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea' 의 참고문헌

  • WHO coronavirus (COVID-19) dashboard
  • The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2
    Ryu DK [2021]
  • SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
    Chen P [2021]
  • Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study
    Cen Y [2020]
  • Regdanvimab : First approval
    Syed YY [2021]
  • Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
    Planas D [2021]
  • REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19
  • Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research
    Stuart EA [2013]
  • Press release: Celltrion’s regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean MFDS
  • Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection
    Bruzzesi E [2021]
  • Monoclonal antibodies for prevention and treatment of COVID-19
    Marovich M [2020]
  • Mild or moderate Covid-19
    Gandhi RT [2020]
  • IDSA guidelines on the treatment and management of patients with COVID-19
  • FDA statement. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant
  • Enhancing response to Omicron SARS-CoV-2 variant
  • Effect of monoclonal antibody treatment on clinical outcomes in ambulatory patients with coronavirus disease 2019
    Anderson B [2021]
  • Early treatment for Covid-19 with SARSCoV-2 neutralizing antibody sotrovimab
    Gupta A [2021]
  • EMA issues advice on use of regdanvimab for treating COVID-19
  • Coronavirus (COVID-19), Republic of Korea. Patient treatment & management
  • Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59
  • COVID-19 treatment guidelines. Clinical spectrum of SARS-CoV-2infection
  • Bamlanivimab plus etesevimab in mild or moderate Covid-19
    Dougan M [2021]
  • An infectious SARS-CoV-2 B. 1. 1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
  • A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
    Kim C [2021]
  • A Neutralizing monoclonal antibody for hospitalized patients with Covid-19